SR9009 CAS:1379686-30-2

CAS NO: 1379686-30-2
SR9009 CAS:1379686-30-2
Description Review
Description

SR9009, also known as Stenabolic, is a synthetic compound that is primarily used for research purposes. It is classified as a SARM (selective androgen receptor modulator) and is sometimes used by athletes and bodybuilders for performance enhancement. The chemical name of SR9009 is ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl) methyl)amino)methyl)pyrrolidine-1-carboxylate.

Molecular formula and formula weight:

The molecular formula of SR9009 is C20H24ClN3O4S and its formula weight is 437.94 g/mol.

CAS NO:

SR9009 cas: 1379686-30-2

Top Searched Keywords on Google and Synonyms on Google:

Some of the top searched keywords on Google for SR9009 include “SR9009 review”, “SR9009 dosage”, “SR9009 results”, “SR9009 benefits”, and “SR9009 side effects”. Synonyms for SR9009 include Stenabolic and Ethyl-3-((4-chlorobenzyl)((4-nitrophenyl)methyl)amino)methyl)pyrrolidine-1-carboxylate.

Health benefits:

SR9009 is primarily a research compound and is not approved for human use. It has been studied for its potential benefits in improving metabolic health, reducing inflammation, and promoting weight loss.

Potential Effects:

SR9009 has been shown to have a positive effect on glucose metabolism and overall metabolic health. It has also been shown to have a positive effect on fat metabolism, which can lead to weight loss. However, it is important to note that the research on SR9009 is limited and there is not enough evidence to support its use as a performance enhancing drug.

Mechanisms:

SR9009 works by binding to the Rev-ErbA nuclear receptor, which is responsible for regulating several biological processes. By binding to this receptor, SR9009 can affect the body’s circadian rhythms, which can help to regulate metabolism, energy levels, and other biological functions.

Safety:

SR9009 is not approved for human use and has not been thoroughly studied for its safety in humans. It is important to exercise caution when using any research chemical, and it is not recommended to use SR9009 for performance enhancement without the supervision of a medical professional.

Side-Effects:

The potential side effects of SR9009 are not well understood, as there has not been enough research on this compound. However, some animal studies have shown that high doses of SR9009 may cause changes in liver function and cholesterol levels.

Dosage information:

As SR9009 is not approved for human use, there is no recommended dosage for this compound. Researchers who are studying this compound should follow appropriate safety guidelines and use the compound only for research purposes.

In conclusion, SR9009 is a synthetic compound that is primarily used for research purposes. It has been studied for its potential benefits in improving metabolic health, reducing inflammation, and promoting weight loss. However, there is not enough evidence to support its use as a performance enhancing drug, and it is not recommended for human use without the supervision of a medical professional. Further research is needed to understand the potential benefits and risks of SR9009.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code